NINLIB 150 mg capsules contains Nilotinib and are prescription medicines used to treat Philadelphia chromosome –positive chronic myeloid leukemia (CML) . They work by blocking abnormal proteins that can cause cancer cells to multiply . it is an anti-cancer medication which is used to treat a specific type of blood cancer called Philadelphia chromosome –positive chronic myeloid leukemia (ph.+ CML) ,and does not treat bacterial infections.
WHAT ARE NINLIB 150 TABLETS?
NINLIB 150 mg capsule is an anti-cancer medication . it works by blocking the action of the abnormal protein that signals cancer cells to multiply . This helps to stop or slow the spread of cancer cells. It is classified as antineoplastic agent , specifically a tyrosine kinase inhibitor (TKI) and a benzamide derivative.
key classification :
- Therapeutic class: Antineoplastic (anti-cancer medication)
- Action class: Tyrosine kinase inhibitor (TKI) –targets and blocks BCR-ABL proteins to stop abnormal cell growth .
- Chemical class : Benzamide derivative
- Active ingredient: Nilotinib
- Role in slowing disease progression : it slows disease progression by acting as a targeted kinase inhibitor that blocks the abnormal BCR-ABL protein, stopping the multiplication of leukemia from advancing to more aggressive stages and helps achieve remission.
WHAT ARE THE MEDICAL USES OF NINLIB 150 TABLETS?
Medical uses of NINLIB 150 tablets are:
1) Idiopathic pulmonary fibrosis (IPF)
NINLIB 150mg is a targeted prescription medicine used to treat Idiopathic pulmonary fibrosis (IPF) by slowing down the decline in lung function and reducing the buildup of scar tissue. It works as an tyrosine kinase inhibitor to block cell signals that trigger excessive fibrosis .
- Slows the progression of lung fibrosis
NINLIB 150 works as a tyrosine kinase inhibitor that helps slow the progression of lung fibrosis . It reduces the annual rate of decline in lung function ,measured as forced vital capacity (FCV) , in patients with conditions like idiopathic pulmonary fibrosis (IPF) and other progressive fibrosing interstitial lung diseases.
- Helps preserve lung function
NINLIB 150 mg act as a tyrosine kinase inhibitor that slows lung scarring and reduces the rate of functional decline in progressive fibrosing lung diseases like idiopathic pulmonary fibrosis. It build up the star tissues in the lungs . It also helps preserve breathing capacity in chronic progressive fibrosing conditions .
2)Progressive pulmonary fibrosis (PPF)
NINLIB 150 mg is a prescription anti-fibrotic medication containing Nintedanib, used to treat progressive pulmonary fibrosis , idiopathic pulmonary fibrosis (IPF), and chronic fibrosing interstitial lung diseases. It works by blocking specific enzymes called tyrosine kinase that trigger scarring and tissue damage in the lungs. It helps in preserving lung function by helps slows down the fast drop in breathing capacity over time. It does not cure the condition ,but stabilizes long-term outcomes for chronic lung diseases.
- Management of chronic fibrosing interstitial lung diseases
NINLIB 150 mg capsule contains Nintedanib, a tyrosine kinase inhibitor used to slow the worsening of scarring in chronic fibrosing interstitial lung diseases. It helps reduce the buildup of fibrosis tissue in the lungs. It done so by blocks specific cell enzymes called tyrosine kinase that trigger scar tissue and lung damage. It is used for idiopathic pulmonary fibrosis (IPF) ,systematic sclerosis –associated interstitial lung disease and other chronic progressive fibrosing interstitial lung diseases.
- Reduces the rate of lung function decline
NINLIB 150 slows lung function decline in conditions like idiopathic pulmonary fibrosis . it is an antifibrotic medication that blocks tyrosine kinase to reduces lung scarring and lung function decline in idiopathic pulmonary fibrosis (IPF) and progressive interstitial lung diseases.
3)Systematic sclerosis –associated interstitial lung Diseases (SSC-ILD)
NINLIB 150 mg taken twice daily is an antifibrotic medication used to slow the loss of lung function . it reduces the annual rate of lung capacity decline by targeting the cellular processes that cause lung scarring. It helps preserve breathing capacity by decreasing the yearly decline in forced vital capacity .
- Helps slows the progression of lung environment
NINLIB 150 mg capsule used to slow the progression of chronic fibrosing interstitial lung diseases and idiopathic pulmonary fibrosis (IPF). It works by blocking specific enzymes that cause inflammation and scarring in the lungs. It reduces the speed at which lung function declines over time. It preserves remaining breathing capacity but cannot reverse existing lung damage.
- Supports long-term respiratory health
NINLIB 150 mg supports long-term respiratory health by slowing down lung tissue scarring and reducing the rate of lung function decline. It is an oral anti-fibrotic medication used for chronic conditions like idiopathic pulmonary fibrosis (IPF). It stops specific enzyme that tell lung tissue to form scars. It also helps keep breathing capacity stable over a long period, even though it does not cure the underlying diseases.
HOW NINLIB 150 TABLETS WORK?
NINLIB 150 mg contains the active ingredient NILOTINIB , a targeted anti-cancer medication classified as a tyrosine kinase inhibitor (TKI) . it treats a specific type of blood cancer called Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) .
It works by the following ways:
- Mechanism of action of Nintedanib
NINTEDANIB is a small molecule , multi-targeted tyrosine kinase inhibitor that blocks key growth factor receptors including FGFR, VEGFR, and PDGFR , preventing cellular signaling ,fibroblast proliferation , and new blood vessel formation.
- Inhibition of multiple tyrosine kinase receptors
NINLIB 150 mg contains the active ingredient nilotinib, a therapy that inhibits the BCR-ABL tyrosine kinase protein, as well as other receptors like PDGFR, KIT and DDR to treat chronic myeloid leukemia. It blocks the abnormal BCR-ABL tyrosine kinase produced by the Philadelphia chromosome.
- Reduction of fibrotic tissue formation
NINLIB 150 mg contains nilotinib, a targeted cancer therapy primarily used for chronic myeloid leukemia (CML) and is not an established clinical treatment for reducing general fibrotic tissue formation. They are dedicated anti-fibrotic tyrosine kinase inhibitors used to reduce lung scarring in idiopathic pulmonary fibrosis. It is an antineoplastic agent for leukemia , not a standard antifibrotic for organ fibrosis management .
CONCLUSION
NINLIB 150 mg tablets are a targeted tyrosine kinase inhibitor therapy used for Philadelphia chromosome –positive chronic myeloid leukemia (CML). The core conditions regarding its role in advanced cancer treatment is that it serves as an effective ,specialized oral option for managing disease progression, achieving remission and treating cases resistant to prior therapies like Imatinib.
FREQUENTLY ASKED QUESTIONS (FAQs):
QUESTION: WHAT ARE NINLIB 150 MG TABLETS USED FOR?
NINLIB 150 mg tablets are used to treat Philadelphia chromosome –positive chronic myeloid leukemia (Ph+ CML) , a type of blood cancer, newly diagnosed cases, and cases resistant or intolerant to prior therapy like imatinib. It act as a targeted tyrosine kinase inhibitor (TKI) . it blocks the BCR_ ABL protein signal to stop abnormal white blood cell multiplication .
QUESTION : HOW DOES NINTEDANIB WORK?
NINTEDANIB is a multi-targeted tyrosine kinase inhibitor that slows lung scarring by blocking specific growth factors, stopping fibroblast cell growth and reducing vessel formation in damaged tissues.
QUESTION: CAN NINLIB 150 TABLETS CURE Pulmonary FIBROSIS ?
No, NINTIB 150 does not cure pulmonary fibrosis. Currently, there is no known cure for idiopathic pulmonary fibrosis (IPF). Instead, NINTIB 150 is a vital management therapy that helps slow down the progression of lung scarring and preserves existing lung function over time.
REFRENCES:
1) https://www.1mg.com/drugs/ninlib-150mg-capsule-931376?wpsrc=Google+Organic+Search
2)
2)https://m.indiamart.com/proddetail/nilotinib-ninlib-150-2856013405691.html
